Skip to content
value.today

Sania Therapeutics, Inc.

🇬🇧 London, United Kingdom, UKBiotechnologyFounded 2021
Total raised
$10 M
2 rounds on record
Latest round
$5 M
May 2024
First round on record
Mar 2022
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Sania Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$5 MNo. 2$2 to $10 million

Sania Therapeutics, Inc.: Raise no. 2, May 2024

Investors in this round

4 investors had bought by the notice of May 21, 2024: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Murray · Executive Officer, Director
  • Joseph Korff · Director
  • Mark Evans · Director
  • Robert Brownstone · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Murray, Chief Executive Officer. Newest notice filed May 21, 2024. Read the notice at the SEC.

equitySEC
Mar 2022$5 MNo. 1$2 to $10 million

Sania Therapeutics, Inc.: Raise no. 1, Mar 2022

Investors in this round

14 investors had bought by the notice of Mar 23, 2022: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Murray · Executive Officer, Director
  • Raj Dattani · Executive Officer, Director
  • Robert Brownstone · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Murray, Chief Executive Officer. Newest notice filed Mar 23, 2022. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sania Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).

    SEC Form D · May 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Sania Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sania Therapeutics, Inc.
NameRoleNamed in
Andrew MurrayExecutive officerMay 2024
Raj DattaniExecutive officerMar 2022
Robert BrownstoneExecutive officerMar 2022
Andrew MurrayDirectorMay 2024
Joseph KorffDirectorMay 2024
Mark EvansDirectorMay 2024
Robert BrownstoneDirectorMay 2024
Raj DattaniDirectorMar 2022